These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 35058126)

  • 21. Adverse Reactions of the Second Dose of the BNT162b2 mRNA COVID-19 Vaccine in Healthcare Workers in Korea.
    Lee YW; Lim SY; Lee JH; Lim JS; Kim M; Kwon S; Joo J; Kwak SH; Kim EO; Jung J; Kwon HS; Kim TB; Kim SH; Bae S
    J Korean Med Sci; 2021 May; 36(21):e153. PubMed ID: 34060261
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adverse reactions to the first and second doses of Pfizer-BioNTech COVID-19 vaccine among healthcare workers.
    Maruyama A; Sawa T; Teramukai S; Katoh N
    J Infect Chemother; 2022 Jul; 28(7):934-942. PubMed ID: 35361536
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Time course of adverse reactions following BNT162b2 vaccination in healthy and allergic disease individuals aged 5-11 years and comparison with individuals aged 12-15 years: an observational and historical cohort study.
    Yoshida M; Kobashi Y; Shimazu Y; Saito H; Yamamoto C; Kawamura T; Wakui M; Takahashi K; Ito N; Nishikawa Y; Zhao T; Tsubokura M
    Eur J Pediatr; 2023 Jan; 182(1):123-133. PubMed ID: 36224435
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety of heterologous primary and booster schedules with ChAdOx1-S and BNT162b2 or mRNA-1273 vaccines: nationwide cohort study.
    Andersson NW; Thiesson EM; Laursen MV; Mogensen SH; Kjær J; Hviid A
    BMJ; 2022 Jul; 378():e070483. PubMed ID: 35831006
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and tolerability of the novel 2019 coronavirus disease (COVID-19) vaccines among people with epilepsy (PwE): A cross-sectional study.
    Massoud F; Ahmad SF; Hassan AM; Alexander KJ; Al-Hashel J; Arabi M
    Seizure; 2021 Nov; 92():2-9. PubMed ID: 34391030
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of Delayed Large Local Reactions After the First Dose of the SARS-CoV-2 mRNA-1273 Vaccine in Japan.
    Higashino T; Yamazaki Y; Senda S; Satou Y; Yonekura Y; Imai K; Arakawa J; Kawano S; Horinosono H; Miura Y
    JAMA Dermatol; 2022 Aug; 158(8):923-927. PubMed ID: 35649530
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BNT162b2 mRNA COVID-19 vaccine Reactogenicity: The key role of immunity.
    Vizcarra P; Haemmerle J; Velasco H; Velasco T; Fernández-Escribano M; Vallejo A; Casado JL
    Vaccine; 2021 Dec; 39(51):7367-7374. PubMed ID: 34802792
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.
    Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC
    JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sex differences in symptoms following the administration of BNT162b2 mRNA COVID-19 vaccine in children below 5 years of age in Germany (CoVacU5): a retrospective cohort study.
    Moor J; Toepfner N; von Meißner WCG; Berner R; Moor MB; Kublickiene K; Strumann C; Chao CM
    Biol Sex Differ; 2024 Sep; 15(1):74. PubMed ID: 39327617
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reactogenicity of the BNT162b2 mRNA vaccine (Pfizer-BioNTech) against COVID-19 in workers of a tertiary hospital.
    Palomo-Palomo C; Guerra-Estévez D; Parrado-González A; Estaire-Gutiérrez J; Reyes-Malia M; Romero-Alonso MM
    Farm Hosp; 2022 Mar; 46(3):152-156. PubMed ID: 36183208
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acute reactions after a homologous primary COVID-19 vaccination series: Analysis of Taiwan V-Watch data.
    Su WJ; Arnold Chan K; Chuang JH; Wang TA; Chen SF; Chang YC; Chen MY; Chang CC; Yang CH
    Vaccine; 2023 Apr; 41(17):2853-2859. PubMed ID: 37029003
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adverse events after administration of the first and second doses of messenger RNA-based COVID-19 vaccines in Japanese subjects aged 12-18 years.
    Ogawa T; Yamada T; Matsumoto Y; Minami K; Kawanishi F; Nakano T; Ukimura A
    J Int Med Res; 2022 Oct; 50(10):3000605221127518. PubMed ID: 36217268
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analysis of COVID-19 Vaccine Type and Adverse Effects Following Vaccination.
    Beatty AL; Peyser ND; Butcher XE; Cocohoba JM; Lin F; Olgin JE; Pletcher MJ; Marcus GM
    JAMA Netw Open; 2021 Dec; 4(12):e2140364. PubMed ID: 34935921
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military.
    Montgomery J; Ryan M; Engler R; Hoffman D; McClenathan B; Collins L; Loran D; Hrncir D; Herring K; Platzer M; Adams N; Sanou A; Cooper LT
    JAMA Cardiol; 2021 Oct; 6(10):1202-1206. PubMed ID: 34185045
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines.
    Montoya JG; Adams AE; Bonetti V; Deng S; Link NA; Pertsch S; Olson K; Li M; Dillon EC; Frosch DL
    Microbiol Spectr; 2021 Dec; 9(3):e0116221. PubMed ID: 34756093
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reactions following Pfizer-BioNTech COVID-19 mRNA vaccination and related healthcare encounters among 7,077 children aged 5-11 years within an integrated healthcare system.
    Malden DE; Gee J; Glenn S; Li Z; Mercado C; Ogun OA; Kim S; Lewin BJ; Ackerson BK; Jazwa A; Weintraub ES; McNeil MM; Tartof SY
    Vaccine; 2023 Jan; 41(2):315-322. PubMed ID: 36351861
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of Systemic Adverse Reactions and Serum SARS-CoV-2 Spike Protein Antibody Levels after Administration of BNT162b2 mRNA COVID-19 Vaccine.
    Takahashi W; Mizuno T; Hara K; Ara Y; Hurutani R; Agatsuma T; Fujimori M
    Intern Med; 2022 Nov; 61(21):3205-3210. PubMed ID: 35989281
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged ≥65 years: a phase 2, randomised, open-label study.
    Izikson R; Brune D; Bolduc JS; Bourron P; Fournier M; Moore TM; Pandey A; Perez L; Sater N; Shrestha A; Wague S; Samson SI
    Lancet Respir Med; 2022 Apr; 10(4):392-402. PubMed ID: 35114141
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real-life safety profile of mRNA vaccines for COVID-19: An analysis of VAERS database.
    Santi Laurini G; Montanaro N; Broccoli M; Bonaldo G; Motola D
    Vaccine; 2023 May; 41(18):2879-2886. PubMed ID: 37024412
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incidence and Characteristics of Delayed Injection Site Reaction to the mRNA-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine (Moderna) in a Cohort of Hospital Employees.
    Jacobson MA; Zakaria A; Maung Z; Hart C; McCalmont TH; Fassett M; Amerson E
    Clin Infect Dis; 2022 Mar; 74(4):591-596. PubMed ID: 34086881
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.